Holen Sie sich die Stockscreener-App
0.1906
11.59%
0.0198
Valion Bio Inc Aktie (VBIO) Neueste Nachrichten
Valion Bio Cash Plunges to $2.1M, Flags Going-Concern Risk - Minichart
Valion Bio (VBIO) investor group reports 1.74M shares, capped at 9.9% stake - Stock Titan
Valion Bio (OTC: VBIO) faces going concern risk and Nasdaq bid price warning - Stock Titan
Valion Bio, Inc. Q2 2026: Net loss $7.1M, EPS $(2.17) — 10-Q Summary - TradingView
Entolimod Could Receive Its First National Registration in Ukraine - Stock Titan
Valion Bio, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
Valion Bio, Inc. (VBIO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Valion Bio Inc. (VBIO) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - Stocktwits
Valion Bio Advances Government-Funded Entolimod Radiation Injury Studies With Data Expected in Early Fall - Yahoo Finance
Valion Bio begins safety study for radiation injury drug - Investing.com
News by ACCESS Newswire on TradingView, 2026-08-12 - TradingView
Valion Bio Plans Mouse Study After Lethal Radiation Exposure - Stock Titan
Valion Bio, Inc. (OTC: VBIO) investors file 13D/A and outline $9M preferred stock plan - Stock Titan
Valion Bio, Inc.Common stock (Nasdaq:VBIO) Stock Quote - FinancialContent
Insiders Who Sold Valion Bio Missed Out On 19% Stock Increase - webull.com
Valion Bio Enters Securities Purchase Agreement With Avenue, Issues Preferred for $750,000 Milestone - TradingView
3i, LP Pushes for Changes at Valion Bio with 9.9% Stake - TradingView
Valion Bio Inc (NASDAQ: VBIO) Share Price, VBIO Stock News, VBIO Share Price & Updates - Kalkine
Murchinson Ltd. Acquires 440,242 Shares in Valion Bio Inc. - GuruFocus
Ukraine could issue an Entolimod decision in as few as 45–60 days - Stock Titan
Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway - Morningstar
Planned cancer trial will test whether Entolimod protects marrow - Stock Titan
Sheba Medical Center to evaluate Valion Bio’s Entolimod in trial By Investing.com - Investing.com Canada
Sheba Medical Center to evaluate Valion Bio’s Entolimod in trial - Investing.com
World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market - PR Newswire
Daily Brief Health Care: JPJ (TCM) Limited(TCM), Abeona Therapeutics , Mani Inc, BioVie , Propanc Biopharma, Tivic Health Systems Inc and more - Smartkarma
Form S-1 Valion Bio Inc For: 17 July By Investing.com - Investing.com Nigeria
Valion Bio Offering Up to 29.4M Shrs and Up to 29.4M Common Warrants - Moomoo
IPO Databook: Valion Bio (VBIO US)Jul 2026 - Smartkarma
Form S-1 Valion Bio Inc For: 17 July - Investing.com India
Form DEF 14A Valion Bio Inc For: 17 July By Investing.com - Investing.com Canada
Valion Bio (OTC: VBIO) asks holders to OK 1-for-5 to 1-for-50 reverse split - Stock Titan
Valion Bio (OTC: VBIO) investor group caps ownership at 9.99% with blocker - Stock Titan
Valion Bio, Inc.: Shareholders Board Members Managers and Company Profile | US8887053085 - marketscreener.com
Valion Bio advances Entolimod platform and manufacturing scale-up - The Globe and Mail
Valion Bio, Inc. Expands Manufacturing Capacity and Pursues Government and International Preparedness Opportunities - marketscreener.com
Valion Bio reports 200-fold Entolimod scale-up, advances govt engagement and oncology plans - TradingView
Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion - Fidelity Investments
Valion Bio (OTC: VBIO) details biodefense and oncology plans - Stock Titan
Valion Bio Reports Entolimod Scale-Up Equal to ~1.3M Potential Human Doses - Stock Titan
Valion Bio (VIBO) Emerging Growth Conference 89 Summary - Quartr
Enterprise value to EBITDA forward of Valion Bio, Inc. – NASDAQ:VBIO - TradingView
Form PRE 14A Valion Bio Inc For: 7 July By Investing.com - Investing.com Nigeria
[PRE 14A] Valion Bio, Inc. Preliminary Proxy Statement - Stock Titan
AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS - AOL.com
Valion Bio (VIBO) Proxy filing Summary - Quartr
VBIOValion Bio Inc Dividends - Finviz
Price to book forward of Valion Bio, Inc. – NASDAQ:VBIO - TradingView
Valion Bio (VBIO) Stock Analysis Report | Financials & Insights - Benzinga
Enterprise value to EBIT forward of Valion Bio, Inc. – NASDAQ:VBIO - TradingView
Price to earnings forward of Valion Bio, Inc. – NASDAQ:VBIO - TradingView
Valion Bio’s Entolimod gets protocol design for radiation syndrome study - Investing.com
Valion Bio, Inc. Actuals & Estimates (NASDAQ:VBIO) - TradingView
AFRRI/NIAID finishes Entolimod test plan for GI radiation illness - Stock Titan
Valion Bio (VBIO) CFO exercises 92 RSUs, holds 618 common shares after conversion - Stock Titan
Valion Bio Completes New Preferred Stock Financing Round - TipRanks
Valion Bio issues preferred shares and warrants in $250,000 private placement By Investing.com - Investing.com South Africa
Valion Bio issues preferred shares and warrants in $250,000 private placement - Investing.com UK
Valion Bio (NASDAQ: VBIO) adds $250,000 via Series B preferred share and warrant sale - Stock Titan
VBIO Price Today: Valion Bio, Inc. Stock Price, Quote & Chart | MEXC - MEXC
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):